Reducing Tau Levels with FDA-Approved Compounds
Author Information
Author(s): Dickey Chad A, Ash Peter, Klosak Natalia, Lee Wing C, Petrucelli Leonard, Hutton Michael, Eckman Christopher B
Primary Institution: Mayo Clinic Jacksonville
Hypothesis
Can FDA-approved compounds effectively reduce total tau protein levels in neuroglioma and neuroblastoma cell lines?
Conclusion
The study found that several FDA-approved compounds can significantly reduce tau protein levels, potentially offering new therapeutic avenues for tau-related neurodegenerative diseases.
Supporting Evidence
- 26 compounds were identified that significantly reduced tau levels.
- 9 compounds showed a reduction in tau levels with minimal effects on cell viability.
- Compounds affecting microtubule dynamics were particularly effective in reducing tau.
Takeaway
Some medicines that doctors already use can help lower a harmful protein in the brain that causes memory problems.
Methodology
The study used a cell-based screening method to test 880 compounds for their ability to reduce tau protein levels in human neuroglioma and neuroblastoma cell lines.
Potential Biases
Potential bias in selecting compounds based on prior knowledge of their effects on tau.
Limitations
The study primarily focused on in vitro results, which may not fully translate to in vivo efficacy.
Participant Demographics
Human neuroglioma and neuroblastoma cell lines were used for testing.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website